Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherClinical Investigations (Human)

A Prospective Randomized, Double-blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors

li huo, Wenjia Zhu, Yuejuan Cheng, Ru Jia, Hong Zhao, Chunmei Bai, Jianming Xu and Shaobo Yao
Journal of Nuclear Medicine February 2021, jnumed.120.253096; DOI: https://doi.org/10.2967/jnumed.120.253096
li huo
1 Peking Union Medical College hospital, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenjia Zhu
2 Peking Union Medical College Hospital, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuejuan Cheng
2 Peking Union Medical College Hospital, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ru Jia
3 The fifth medical center, General Hospital of PLA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Zhao
4 Chinese Academy of Medical Sciences and Peking Union Medical College;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunmei Bai
2 Peking Union Medical College Hospital, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianming Xu
5 The fifth Medical Center, General Hospital of PLA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaobo Yao
6 The First Affiliated Hospital of Fujian Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shaobo Yao
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 are somatostatin receptor subtype 2 (SSTR2) specific antagonists used for PET/CT imaging. The purpose of this study was to evaluate the safety, biodistribution, and dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors (NETs). Methods: Patients were equally randomized into two arms: Arm A, 68Ga-NODAGA-LM3; Arm B, 68Ga-DOTA-LM3. Serial PET scans were acquired at 5, 15, 30, 45, 60, and 120 minutes after 68Ga-NODAGA-LM3 (200 MBq ± 11 MBq/40 μg total peptide mass) or 68Ga-DOTA-LM3 (172 MBq ± 21 MBq/40 μg total peptide mass) injection. The biodistribution in normal organs, tumor uptake, and safety were assessed. Radiation dosimetry was calculated using OLINDA/EXM (version 1.0). Results: Sixteen patients, 8 in each arm, were recruited in the study. Both tracers were well tolerated in most patients. Two patients in Arm B had nausea (G2) and one of them had vomiting (G1). The PET images of other fourteen patients were further analyzed. Significantly lower organ uptake was observed in the pituitary, parotids, liver, spleen, pancreas, adrenal, stomach, small intestine, and kidneys with 68Ga-DOTA-LM3 compared to 68Ga-NODAGA-LM3. A total of 38 lesions were analyzed, including 18 lesions on 68Ga-NODAGA-LM3 and 20 lesions on 68Ga-DOTA-LM3. Both tracers showed good tumor uptake and retention. With 68Ga-NODAGA-LM3, the tracer accumulation in tumor lesions increased by 138%, from an average SUVmax of 31.3 ± 19.7 at 5 minutes to 74.6 ± 56.3 at 2h. With 68Ga-DOTA-LM3, the tumor uptake rapidly reached a high level at 5 minutes after injection, with an average SUVmax of 36.6 ± 23.6, and continued to increase to 45.3 ± 29.3 until 30 minutes post-injection. Urinary bladder wall is the organ receiving the highest absorbed dose in both arms. The mean effective dose was 0.026 ± 0.003 mSv/MBq for 68Ga-NODAGA-LM3 and 0.025 ± 0.002 mSv/MBq for 68Ga-DOTA-LM3. Conclusion: Both 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 show favorable biodistribution, high tumor uptake, and good tumor retention, resulting in high image contrast. The dosimetric data is comparable to other 68Ga-labeled SSTR2 antagonists. Further studies are required to look into the potential antagonistic effects of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3.

  • Neuroendocrine
  • Oncology: Endocrine
  • Radiobiology/Dosimetry
  • 68Ga-DOTA-LM3
  • 68Ga-NODAGA-LM3
  • PET/CT
  • Somatostatin receptor antagonist
  • neuroendocrine tumor
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Prospective Randomized, Double-blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
A Prospective Randomized, Double-blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors
li huo, Wenjia Zhu, Yuejuan Cheng, Ru Jia, Hong Zhao, Chunmei Bai, Jianming Xu, Shaobo Yao
Journal of Nuclear Medicine Feb 2021, jnumed.120.253096; DOI: 10.2967/jnumed.120.253096

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Prospective Randomized, Double-blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors
li huo, Wenjia Zhu, Yuejuan Cheng, Ru Jia, Hong Zhao, Chunmei Bai, Jianming Xu, Shaobo Yao
Journal of Nuclear Medicine Feb 2021, jnumed.120.253096; DOI: 10.2967/jnumed.120.253096
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • 18F-FDG PET/MRI for staging and interim response assessment in pediatric and adolescent Hodgkin lymphoma: a prospective study with 18F-FDG PET/CT as reference standard
  • Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
Show more Clinical Investigations (Human)

Clinical (Oncology: Endocrine/Neuroendocrine)

  • Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE
  • The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis
Show more Clinical (Oncology: Endocrine/Neuroendocrine)

Similar Articles

Keywords

  • Neuroendocrine
  • Oncology: Endocrine
  • Radiobiology/Dosimetry
  • 68Ga-DOTA-LM3
  • 68Ga-NODAGA-LM3
  • PET/CT
  • somatostatin receptor antagonist
  • neuroendocrine tumor
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire